Assessing West Pharmaceutical Services (WST) Valuation After Mixed Returns And Premium P/E Multiple

West Pharmaceutical Services: Event Context and Stock Snapshot

West Pharmaceutical Services (WST) has attracted fresh attention after recent trading data, with the share price at $241.40 and mixed short term and longer term returns prompting investors to reassess expectations around this injectable drug packaging specialist.

See our latest analysis for West Pharmaceutical Services.

Recent trading has been choppy, with a 1 day share price return of 1.84% contrasting with a 90 day share price return decline of 13.01%. The 1 year total shareholder return of 4.46% sits against a 3 year total shareholder return decline of 27.53%, suggesting momentum has been fading over the longer horizon.

If this kind of mixed performance has you reassessing your watchlist, it can help to see what else is catching attention in healthcare. You can scan for other medical and pharma names tapping into AI trends via 36 healthcare AI stocks.

With West Pharmaceutical Services posting steady annual revenue and net income growth alongside a recent 13.01% 90 day share price decline, the key question is whether the current US$241.40 level reflects undervaluation or already prices in future growth.

Most Popular Narrative: 29% Undervalued

With West Pharmaceutical Services last closing at $241.40 against a narrative fair value of $338.57, the most followed storyline frames the shares as meaningfully discounted based on long term earnings power and margin potential.

The introduction of an automated line for HVP delivery devices later in 2025 to early 2026 is expected to improve margins by driving operational efficiencies and scale, enhancing net margins. The increase in demand and the transition to higher margin HVP components, supported by approximately 340 Annex 1 projects, is likely to positively impact both revenue and net margins due to a favorable mix shift.

Read the complete narrative.

Curious what kind of revenue mix, margin profile, and earnings base would support that fair value at a 7.79% discount rate and a premium P/E multiple. The full narrative spells out the growth path, the margin rebuild, and the pricing assumptions sitting behind that $338.57 figure.

Result: Fair Value of $338.57 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, that upbeat fair value story can quickly unravel if softer revenue assumptions play out, or if higher tariffs and shifting demand weigh more heavily on margins than expected.

Find out about the key risks to this West Pharmaceutical Services narrative.

Another Angle On Valuation: Earnings Multiple Sends A Different Signal

The upbeat fair value narrative sits awkwardly next to what the current P/E is saying. West Pharmaceutical Services trades on 35.2x earnings, versus a 21.7x fair ratio, 31.5x for the wider North American Life Sciences group, and 29.5x for peers. This points more to valuation risk than to a clear bargain. Which story do you lean toward?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If this mix of optimism and valuation risk leaves you unsure, it can help to move quickly, review the full picture, and weigh up the 2 key rewards

Looking for more investment ideas?

If West Pharmaceutical Services is on your radar, do not stop there. Broaden your watchlist with a few focused stock ideas that fit clear, practical themes.

• Target potential value opportunities by scanning 55 high quality undervalued stocks that combine quality fundamentals with prices that may not fully reflect those characteristics.
• Build a steadier income stream by reviewing 12 dividend fortresses that offer higher yields while still passing key financial health checks.
• Prioritize resilience by checking 74 resilient stocks with low risk scores that score well on balance sheet strength and business risk factors.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com